Advaxis (ADXS) 10-Q 13 Mar 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Jan. 31, 2020	Feb. 29, 2020
Document And Entity Information
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	0001100397
Document Type	10-Q
Document Period End Date	Jan. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		60,244,843
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Jan. 31, 2020	Oct. 31, 2019
Current Assets:
Cash and cash equivalents	$ 34,156	$ 32,363
Deferred expenses	2,032	2,353
Prepaid expenses and other current assets	965	1,433
Total current assets	37,153	36,149
Property and equipment (net of accumulated depreciation)	4,121	4,350
Intangible assets (net of accumulated amortization)	4,490	4,575
Operating right-of-use asset (net of accumulated amortization)	5,402
Other assets	182	183
Total assets	51,348	45,257
Current liabilities:
Accounts payable	444	976
Accrued expenses	2,657	3,478
Common stock warrant liability	54	19
Current portion of operating lease liability	857
Other current liabilities		48
Total current liabilities	4,012	4,521
Operating lease liability, net of current portion	5,788
Other liabilities		1,205
Total liabilities	9,800	5,726
Commitments and contingencies - Note 10
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized, 0 shares issued and outstanding at January 31, 2020 and October 31, 2019 Liquidation preference of $0 at January 31, 2020 and October 31, 2019
Common stock, $0.001 par value, 170,000,000 shares authorized, 60,236,599 and 50,201,671 shares issued and outstanding at January 31, 2020 and October 31, 2019, respectively	60	50
Additional paid-in capital	433,614	423,750
Accumulated deficit	(392,126)	(384,269)
Total stockholders' equity	41,548	39,531
Total liabilities and stockholders' equity	$ 51,348	$ 45,257

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jan. 31, 2020	Oct. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference value	$ 0	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	60,236,599	50,201,671
Common stock, shares outstanding	60,236,599	50,201,671

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Income Statement [Abstract]
Revenue	$ 3	$ 19,689
Operating expenses:
Research and development expenses	4,859	6,707
General and administrative expenses	3,030	2,666
Total operating expenses	7,889	9,373
(Loss) income from operations	(7,886)	10,316
Other income (expense):
Interest income	66	146
Net changes in fair value of derivative liabilities	(37)	2,409
Other expense		(4)
Net (loss) income before benefit for income taxes	(7,857)	12,867
Income tax expense		50
Net (loss) income	$ (7,857)	$ 12,817
Net (loss) income per common share, basic and diluted	$ (0.15)	$ 2.76
Weighted average number of common shares outstanding, basic	51,747,246	4,642,718
Weighted average number of common shares outstanding, diluted	51,747,246	4,642,817

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
OPERATING ACTIVITIES
Net (loss) income	$ (7,857)	$ 12,817
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Stock compensation	242	622
Employee stock purchase plan expense		1
Loss (gain) on change in value of warrants	37	(2,409)
Abandonment of intangible assets	232	244
Depreciation expense	229	285
Amortization expense of intangible assets	91	96
Amortization of right-of-use asset	181
Change in operating assets and liabilities:
Accounts receivable		143
Prepaid expenses and other current assets	789	(660)
Other assets	1
Accounts payable and accrued expenses	(1,462)	(4,707)
Deferred revenue		(18,318)
Operating lease liabilities	(191)
Other liabilities		16
Net cash used in operating activities	(7,708)	(11,870)
INVESTING ACTIVITIES
Purchase of property and equipment		(45)
Cost of intangible assets	(238)	(507)
Net cash used in investing activities	(238)	(552)
FINANCING ACTIVITIES
Net proceeds of issuance of common stock	9,737
Proceeds from employee stock purchase plan	2	14
Employee tax withholdings paid on equity awards		(11)
Tax shares sold to pay for employee tax withholdings on equity awards		11
Net cash provided by financing activities	9,739	14
Net increase (decrease) in cash, cash equivalents and restricted cash	1,793	(12,408)
Cash, cash equivalents and restricted cash at beginning of year	32,363	45,118
Cash, cash equivalents and restricted cash at end of year	34,156	32,710
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for taxes		50
SUPPLEMENTAL DISCLOSURE OF NON-CASH AND FINANCING ACTIVITIES
Amounts accrued for offering costs	109
Warrant liability reclassified into equity	$ 2

Nature of Operations

Nature of Operations	3 Months Ended
	Jan. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	1. NATURE OF OPERATIONS Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes Lm Lm Lm Lm TM ● Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants; ● Attacking the tumor by generating a strong, cancer-specific T cell response; and ● Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells. Advaxis’ proprietary Lm Lm Liquidity and Financial Condition The Company has not yet commercialized any human products and the products that are being developed have not generated significant revenue. As a result, the Company has experienced recurring losses and requires significant cash resources to execute its business plans. Historically, the Company’s major sources of cash have been comprised of proceeds from various public and private offerings of its common stock, clinical collaborations, option and warrant exercises, and interest income. From October 2013 through January 2020, the Company raised approximately $302.7 million in gross proceeds ($10.5 million in the first quarter of fiscal year 2020) from various public and private offerings of its common stock. In Note 2 of the notes to the Company’s audited financial statements as of and for the year ended October 31, 2019, management stated that the Company had incurred significant losses, negative operating cash flows and as of those dates needed to raise additional funds to meet its obligations and sustain its operations. As a result, the Company concluded that there was substantial doubt as to the Company’s ability to continue as a going concern. As of January 31, 2020, the Company had approximately $34.2 million in cash and cash equivalents. The Company has significantly reduced its operating expenses to $38.9 million for the fiscal year ended October 31, 2019 as compared to $76.4 million during the fiscal year ended October 31, 2018. Furthermore, the Company expects cash requirements to approximate $29 million for fiscal year 2020, which includes approximately $6 million in non-recurring costs related to programs that are winding down. The Company believes to have sufficient capital to fund its obligations, as they become due, in the ordinary course of business until at least August 2021. Given our cash balances including funds raised of $10.5 million (which yielded net proceeds of $9.6 million) in January 2020 and based on its budgeted, reduced cash flow requirements for the next twelve months from the date of filing, the Company believes such funds are sufficient to support ongoing operations at least one year after the issuance of these financial statements. Regardless of the results of any ongoing clinical trial, we have control over our expenditures and have the ability to adjust spending accordingly based on the budgeted cash flow requirements developed and the excess cash on hand.

Summary of Significant Accounti

Summary of Significant Accounting Policies and Basis of Presentation	3 Months Ended
	Jan. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Basis of Presentation	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Basis of Presentation/Estimates The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited condensed balance sheet as of January 31, 2020 has been derived from the Company’s October 31, 2019 audited financial statements. In the opinion of management, the unaudited interim condensed financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented. Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates. These unaudited interim condensed financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2019 and notes thereto contained in the Company’s annual report on Form 10-K, as filed with the SEC on December 20, 2019. Leases Effective November 1, 2019, the Company adopted ASC Topic 842, Leases (“ASC 842”) using the modified retrospective transition approach by applying the new standard to all leases existing as of the date of initial application. Results and disclosure requirements for reporting periods beginning after November 1, 2019 are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported in accordance with the previous guidance in ASC 840, Leases. At the inception of an arrangement, the Company determines whether an arrangement is or contains a lease based on the facts and circumstances present in the arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Most leases with a term greater than one year are recognized on the balance sheet as operating lease right-of-use assets and current and long-term operating lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes the initial lease term in its assessment of a lease arrangement. Options to extend a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued rent. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. Recent Accounting Standards Recently Adopted Accounting Standards On November 1, 2019, the Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which establishes ASC 842 and supersedes the lease accounting guidance under ASC 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. We adopted the new guidance using the modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and not restating comparative periods. In adopting the new standard, the Company elected to utilize the available package of practical expedients permitted under the transition guidance within the new standard, which does not require the reassessment of the following: (i) whether existing or expired arrangements are or contain a lease, (ii) the lease classification of existing or expired leases, and (iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. Additionally, the Company elected to combine lease and non-lease components and to exclude leases with a term of 12 months or less. As of the November 1, 2019 effective date, the Company has identified one operating lease arrangement and one short-term lease in which it is a lessee. The adoption of ASC 842 resulted in the recognition of an operating lease liability and a right-of-use asset of approximately $6.8 million and $5.6 million, respectively, on the Company’s balance sheet relating to its leases, with the difference relating to reclassifications of the current accrued rent liability and the current lease incentive obligation of approximately $0.9 million and $0.3 million, respectively, as reductions to the right-of-use-asset for its operating lease. The adoption of the standard did not have a material effect on the Company’s condensed statements of operations or condensed statements of cash flows. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

Property and Equipment

Property and Equipment	3 Months Ended
	Jan. 31, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	3. PROPERTY AND EQUIPMENT Property and equipment, net consists of the following (in thousands): January 31, 2020 October 31, 2019 Leasehold improvements $ 2,335 $ 2,335 Laboratory equipment 3,405 3,405 Furniture and fixtures 744 744 Computer equipment 409 409 Construction in progress 83 83 Total property and equipment 6,976 6,976 Accumulated depreciation and amortization (2,855 ) (2,626 ) Net property and equipment $ 4,121 $ 4,350 Depreciation expense for the three months ended January 31, 2020 and 2019 was approximately $0.2 million and $0.3 million, respectively.

Intangible Assets

Intangible Assets	3 Months Ended
	Jan. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	4. INTANGIBLE ASSETS Intangible assets, net consist of the following (in thousands): January 31, 2020 October 31, 2019 Patents $ 5,811 $ 5,833 Licenses 777 777 Software 117 117 Total intangibles 6,705 6,727 Accumulated amortization (2,215 ) (2,152 ) Intangible assets $ 4,490 $ 4,575 The expirations of the existing patents range from 2020 to 2040 but the expirations can be extended depending upon market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. Patent applications having a net book value of approximately $0.2 million were abandoned and were charged to general and administrative expenses in the statement of operations for each of the three months ended January 31, 2020 and 2019, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the statement of operations aggregated approximately $0.1 million for each of the three months ended January 31, 2020 and 2019. Management has reviewed its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet for patents and licenses related to axalimogene filolisbac (AXAL), ADXS-HOT, ADXS-PSA and ADXS-HER2 and other products that are in development. However, if a competitor were to gain FDA approval for a treatment before us or if future clinical trials fail to meet the targeted endpoints, the Company would likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of its estimated book value. Lastly, if the Company is unable to raise enough capital to continue funding its studies and developing its intellectual property, the Company would likely record an impairment to these assets. At January 31, 2020, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands): Fiscal Year ended October 31, 2020 (Remaining) $ 249 2021 332 2022 332 2023 332 2024 332 Thereafter 2,913 Total $ 4,490

Accrued Expenses

Accrued Expenses	3 Months Ended
	Jan. 31, 2020
Payables and Accruals [Abstract]
Accrued Expenses	5. ACCRUED EXPENSES The following table represents the major components of accrued expenses (in thousands): January 31, 2020 October 31, 2019 Salaries and other compensation $ 1,108 $ 158 Vendors 1,189 3,194 Professional fees 360 126 Total accrued expenses $ 2,657 $ 3,478

Common Stock Purchase Warrants

Common Stock Purchase Warrants and Warrant Liability	3 Months Ended
	Jan. 31, 2020
Common Stock Purchase Warrants And Warrant Liability
Common Stock Purchase Warrants and Warrant Liability	6. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY Warrants As of January 31, 2020, there were outstanding warrants to purchase 5,405,726 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows: Exercise Number of Shares Expiration Date Summary of Warrants $ - 334,838 July 2024 July 2019 Public Offering $ 281.25 25 N/A Other Warrants $ 0.372 70,863 September 2024 September 2018 Public Offering $ 1.25 5,000,000 July 2025 January 2020 Public Offering Grand Total 5,405,726 As of October 31, 2019, there were outstanding warrants to purchase 432,142 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows: Exercise Number of Shares Expiration Date Summary of Warrants $ - 359,838 July 2024 July 2019 Public Offering $ 281.25 25 N/A Other Warrants $ 0.372 72,279 September 2024 September 2018 Public Offering Grand Total 432,142 A summary of warrant activity was as follows (In thousands, except share and per share data): Shares Weighted Weighted Aggregate Outstanding and exercisable warrants at October 31, 2019 432,142 $ 0.08 4.76 $ 114,069 Issued 5,000,000 $ 1.25 Exercised* (26,416 ) $ 0.24 Outstanding and exercisable warrants at January 31, 2020 5,405,726 $ 1.16 5.40 $ 322,542 * Includes the cashless exercise of 25,000 warrants that resulted in the issuance of 25,000 shares of common stock. As of January 31, 2020, the Company had 5,334,863 of its total 5,405,726 outstanding warrants classified as equity (equity warrants). At October 31, 2019, the Company had 359,863 of its total 432,142 outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the relative fair value method, in the stockholders’ equity section of the balance sheet. Warrant Liability As of January 31, 2020, the Company had 70,863 of its total 5,405,726 outstanding warrants classified as liabilities (liability warrants). At October 31, 2019, the Company had 72,279 of its total 432,142 outstanding warrants classified as liabilities (liability warrants). These warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. As of January 31, 2020, the down round feature was triggered three times and the exercise price of the warrants were reduced from $22.50 to $0.372. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which settlement in other than cash would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequent reporting date. In measuring the warrant liability at January 31, 2020 and October 31, 2019, the Company used the following inputs in its Monte Carlo simulation model: January 31, 2020 October 31, 2019 Exercise Price $ 0.37 $ 0.37 Stock Price $ 0.86 $ 0.32 Expected Term 4.62 years 4.87 years Volatility % 103.18 % 100.99 % Risk Free Rate 1.32 % 1.51 %

Share Based Compensation

Share Based Compensation	3 Months Ended
	Jan. 31, 2020
Share-based Payment Arrangement [Abstract]
Share Based Compensation	7. SHARE BASED COMPENSATION The following table summarizes share-based compensation expense included in the condensed statements of operations (in thousands): Three Months Ended January 31, 2020 2019 Research and development $ 91 $ 323 General and administrative 151 299 Total $ 242 $ 622 Restricted Stock Units (RSUs) A summary of the Company’s RSU activity and related information for the three months ended January 31, 2020 is as follows: Number of Weighted-Average Grant Unvested as of October 31, 2019 14,706 $ 47.62 Vested (2,957 ) 124.77 Cancelled (105 ) 101.72 Unvested as of January 31, 2020 11,644 $ 27.53 As of January 31, 2020, there was approximately $0.2 million of unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a remaining weighted average vesting period of 1.05 years. As of January 31, 2020, the aggregate fair value of non-vested RSUs was approximately $10,000. Employee Stock Awards Common Stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 2,957 shares and 9,847 shares during the three months ended January 31, 2020 and 2019, respectively. Total stock compensation expense associated with employee awards for the three months ended January 31, 2020 and 2019 was approximately $56,000 and $0.3 million, respectively. Stock Options A summary of changes in the stock option plan for the three months ended January 31, 2020 is as follows: Number of Weighted-Average Outstanding at October 31, 2019 560,490 $ 71.56 Canceled or Expired (7,044 ) 24.10 Outstanding at January 31, 2020 553,446 72.17 Vested and Exercisable at January 31, 2020 268,371 $ 141.37 Total compensation cost related to the Company’s outstanding stock options, recognized in the condensed statement of operations for the three months ended January 31, 2020 and 2019 was approximately $0.2 million and $0.3 million, respectively. As of January 31, 2020, there was approximately $1.1 million of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of 1.41 years. As of January 31, 2020, the aggregate intrinsic value of vested and exercisable options was $0. In determining the fair value of the stock options granted during the three months ended January 31, 2019, the Company used the following inputs in its Black-Scholes Merton (“BSM”) model (no options were granted during the three months ended January 31, 2020): Three Months Ended Expected Term 5.50-6.51 years Expected Volatility 90.29%-99.32 % Expected Dividends 0 % Risk Free Interest Rate 2.65%-3.15 % 2018 Employee Stock Purchase Plan During the three months ended January 31, 2020, the Company issued 5,555 shares that were purchased under the 2018 Employee Stock Purchase Plan (“ESPP”).

Net Income (Loss) Per Share

Net Income (Loss) Per Share	3 Months Ended
	Jan. 31, 2020
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	8 NET INCOME (LOSS) PER SHARE Basic and diluted earnings per share is calculated as follows (in thousands, except share and per share data): Three Months Ended January 31, 2020 2019 Numerator : Net (loss) income $ (7,857 ) $ 12,817 Earnings attributable to common stockholders – basic and diluted (7,857 ) 12,817 Denominator: Weighted-average number of common shares used in earnings per share - basic 51,412,408 4,642,718 Effect of dilutive stock options - 99 Weighted-average number of common shares used in earnings per share - diluted 51,412,408 4,642,817 Earnings per share – basic and diluted $ (0.15 ) $ 2.76 The following potentially dilutive securities, prior to the use of the treasury stock method, have been excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive: As of January 31, 2020 2019 Warrants 5,405,726 944,636 Stock Options 553,446 383,292 Restricted Stock Units 11,644 20,258 Total 5,970,816 1,348,186

Collaboration and Licensing Agr

Collaboration and Licensing Agreements	3 Months Ended
	Jan. 31, 2020
Business Combinations [Abstract]
Collaboration and Licensing Agreements	9. COLLABORATION AND LICENSING AGREEMENTS Elanco Animal Health (formerly Aratana Therapeutics) During the year fiscal year ended October 31, 2018, the USDA’s Center for Veterinary Biologics granted Aratana conditional approval for its canine osteosarcoma vaccine using Advaxis’ technology. During the three months ended January 31, 2020 and 2019, Advaxis recognized royalty revenue totaling approximately $3,000 and $2,000, respectively, from Aratana’s sales of the canine osteosarcoma vaccine. On July 16, 2019, Aratana announced their shareholders approved a merger agreement with Elanco Animal Health (“Elanco”) whereby Elanco will be the majority shareholder of Aratana. All of the terms of the Aratana Agreement remain in effect.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Jan. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. COMMITMENTS AND CONTINGENCIES Legal Proceedings Stendhal On September 19, 2018, Stendhal filed a Demand for Arbitration before the International Centre for Dispute Resolution (Case No. 01-18-0003-5013) relating to the Co-development and Commercialization Agreement with Especificos Stendhal SA de CV (the “Stendhal Agreement”). In the demand, Stendhal alleged that (i) the Company breached the Stendhal Agreement when it made certain statements regarding its AIM2CERV program, (ii) that Stendhal was subsequently entitled to terminate the Agreement for cause, which it did so at the time and (iii) that the Company owes Stendhal damages pursuant to the terms of the Stendhal Agreement. Stendhal is seeking to recover $3 million paid to the Company in 2017 as support payments for the AIM2CERV clinical trial along with approximately $0.3 million in expenses incurred. Stendhal is also seeking fees associated with the arbitration and interest. The Company has answered Stendhal’s Demand for Arbitration and denied that it breached the Stendhal Agreement. The Company also alleges that Stendhal breached its obligations to the Company by, among other things, failing to make support payments that became due in 2018 and that Stendhal therefore owes the Company $3 million. Advaxis is also seeking fees associated with the arbitration and interest. On April 2, 2019, the Arbitrator denied the Company’s early application for summary disposition of Stendhal’s claims. No reasoning was provided. From October 21-23, 2019, an evidentiary hearing for the arbitration was conducted, and on November 23, 2019, the arbitrator requested that the parties submit post-hearing briefs which were submitted on January 15, 2020. On February 20, 2020, the parties were notified that the hearings have been declared closed as of February 1, 2020. At this time, the Company is unable to predict the likelihood of an unfavorable outcome.

Leases

Leases	3 Months Ended
	Jan. 31, 2020
Leases [Abstract]
Leases	11. LEASES Operating Leases The Company leases its corporate office and manufacturing facility in Princeton, New Jersey under an operating lease that expires in November 2025. The Company has the option to renew the lease term for two additional five-year terms. The renewal periods were not included the lease term for purposes of determining the lease liability or right-of-use asset. The Company has provided a security deposit of approximately $182,000, which is recorded as Other Assets in the condensed balance sheet. The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities: ● As the Company does not have sufficient insight to determine an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company utilized a synthetic credit rating model to determine a benchmark for its incremental borrowing rate for its leases. The benchmark rate was adjusted to arrive at an appropriate discount rate for the lease. ● Since the Company elected to account for each lease component and its associated non-lease components as a single combined component, all contract consideration was allocated to the combined lease component. ● Renewal option periods have not been included in the determination of the lease terms as they are not deemed reasonably certain of exercise. ● Variable lease payments, such as common area maintenance, real estate taxes, and property insurance are not included in the determination of the lease’s right-of-use asset or lease liability. Supplemental balance sheet information related to leases as of January 31, 2020 was as follows (in thousands): Operating Leases:  Operating lease right-of-use assets $ 5,402 Operating lease liability $ 857 Operating lease liability, net of current portion 5,788 Total operating lease liabilities $ 6,645 Supplemental lease expense related to leases was as follows (in thousands): Lease Cost (in thousands) Statements of Operations Classification For the Three Operating lease cost General and administrative 290 Short-term lease cost General and administrative 85 Variable lease cost General and administrative $ 141 Total lease expense $ 516 Other information related to leases where the Company is the lessee is as follows: For the Three Weighted-average remaining lease term 5.8 years Weighted-average discount rate 6.5 % Supplemental cash flow information related to operating leases was as follows: For the Three Cash paid for operating lease liabilities $ 300 Future minimum lease payments under non-cancellable leases as of January 31, 2020 were as follows: Fiscal Year ended October 31, 2020 (Remaining) $ 933 2021 1,318 2022 1,369 2023 1,395 2024 1,419 Thereafter 1,564 Total minimum lease payments 7,998 Less: Imputed interest (1,353 ) Total $ 6,645 Under ASC 840, future minimum payments under the Company’s operating lease were as follows (in thousands): Fiscal Year ended October 31, 2020 $ 1,233 2021 1,318 2022 1,369 2023 1,395 2024 1,419 Thereafter 1,564 Total $ 8,298 Under ASC 840, rent expense for each of the years ended October 31, 2019 and 2018 was approximately $1.2 million.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Jan. 31, 2020
Equity [Abstract]
Stockholders' Equity	12. STOCKHOLDERS’ EQUITY A summary of the changes in stockholders’ equity for the three months ended January 31, 2020 and 2019 is presented below (in thousands, except share data): Preferred Stock Common Stock Additional Accumulated Total Shares Amount Shares Amount Capital Deficit Equity Balance at November 1, 2018 - $ - 4,634,189 $ 5 $ 391,703 $ (367,657 ) $ 24,051 Stock based compensation - - 9,811 - 622 - 622 Tax withholdings paid on equity awards - - - - (11 ) - (11 ) Tax shares sold to pay for tax withholdings on equity awards - - - - 11 - 11 Issuance of shares to employees under ESPP Plan - - 2,007 - 9 - 9 ESPP Expense - - - - 1 1 Net Income - - - - - 12,817 12,817 Balance at January 31, 2019 - $ - 4,646,007 $ 5 $ 392,335 $ (354,840 ) $ 37,500 Preferred Stock Common Stock Additional Accumulated Total Shares Amount Shares Amount Capital Deficit Equity Balance at November 1, 2019 - $ - 50,201,671 $ 50 $ 423,750 $ (384,269 ) $ 39,531 Stock based compensation - - 2,957 - 242 - 242 Advaxis public offerings - - 10,000,000 10 9,618 - 9,628 Warrant exercises - - 26,416 - 2 - 2 Issuance of shares to employees under ESPP Plan - - 5,555 - 2 - 2 Net Income - - - - - (7,857 ) (7,857 ) Balance at January 31, 2020 - $ - 60,236,599 $ 60 $ 433,614 $ (392,126 ) $ 41,548 In January 2020, the Company closed on an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $1.05, for gross proceeds of $10.5 million. In addition, the Company also undertook a concurrent private placement of warrants to purchase up to 5,000,000 shares of common stock. The warrants have an exercise price per share of $1.25, are exercisable during the period beginning on the six-month anniversary of the date of its issuance (the “Initial Exercise Date”) and will expire on the fifth anniversary of the Initial Exercise Date. The warrants also provide that if there is no effective registration statement registering, or no current prospectus available for, the issuance or resale of the warrant shares, the warrants may be exercised via a cashless exercise. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $9.6 million.

Fair Value

Fair Value	3 Months Ended
	Jan. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value	13. FAIR VALUE The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: ● Level 1 — Quoted prices in active markets for identical assets or liabilities. ● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities. ● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities. The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of January 31, 2020 and October 31, 2019: January 31, 2020 Level 1 Level 2 Level 3 Total Common stock warrant liability, warrants exercisable at $0.372 through September 2024 - - $ 54 $ 54 October 31, 2019 Level 1 Level 2 Level 3 Total Common stock warrant liability, warrants exercisable at $0.372 through September 2024 - - $ 19 $ 19 The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities: January 31, 2020 Beginning balance $ 19 Warrant Exercises (2 ) Change in fair value 37 Ending Balance $ 54

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Basis of Presentation (Policies)	3 Months Ended
	Jan. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation/Estimates	Basis of Presentation/Estimates The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited condensed balance sheet as of January 31, 2020 has been derived from the Company’s October 31, 2019 audited financial statements. In the opinion of management, the unaudited interim condensed financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented. Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates. These unaudited interim condensed financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2019 and notes thereto contained in the Company’s annual report on Form 10-K, as filed with the SEC on December 20, 2019.
Leases	Leases Effective November 1, 2019, the Company adopted ASC Topic 842, Leases (“ASC 842”) using the modified retrospective transition approach by applying the new standard to all leases existing as of the date of initial application. Results and disclosure requirements for reporting periods beginning after November 1, 2019 are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported in accordance with the previous guidance in ASC 840, Leases. At the inception of an arrangement, the Company determines whether an arrangement is or contains a lease based on the facts and circumstances present in the arrangement. An arrangement is or contains a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Most leases with a term greater than one year are recognized on the balance sheet as operating lease right-of-use assets and current and long-term operating lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes the initial lease term in its assessment of a lease arrangement. Options to extend a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as prepaid or accrued rent. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates.
Recent Accounting Standards	Recent Accounting Standards Recently Adopted Accounting Standards On November 1, 2019, the Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which establishes ASC 842 and supersedes the lease accounting guidance under ASC 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. We adopted the new guidance using the modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and not restating comparative periods. In adopting the new standard, the Company elected to utilize the available package of practical expedients permitted under the transition guidance within the new standard, which does not require the reassessment of the following: (i) whether existing or expired arrangements are or contain a lease, (ii) the lease classification of existing or expired leases, and (iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. Additionally, the Company elected to combine lease and non-lease components and to exclude leases with a term of 12 months or less. As of the November 1, 2019 effective date, the Company has identified one operating lease arrangement and one short-term lease in which it is a lessee. The adoption of ASC 842 resulted in the recognition of an operating lease liability and a right-of-use asset of approximately $6.8 million and $5.6 million, respectively, on the Company’s balance sheet relating to its leases, with the difference relating to reclassifications of the current accrued rent liability and the current lease incentive obligation of approximately $0.9 million and $0.3 million, respectively, as reductions to the right-of-use-asset for its operating lease. The adoption of the standard did not have a material effect on the Company’s condensed statements of operations or condensed statements of cash flows. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Jan. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consists of the following (in thousands): January 31, 2020 October 31, 2019 Leasehold improvements $ 2,335 $ 2,335 Laboratory equipment 3,405 3,405 Furniture and fixtures 744 744 Computer equipment 409 409 Construction in progress 83 83 Total property and equipment 6,976 6,976 Accumulated depreciation and amortization (2,855 ) (2,626 ) Net property and equipment $ 4,121 $ 4,350

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Jan. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets	Intangible assets, net consist of the following (in thousands): January 31, 2020 October 31, 2019 Patents $ 5,811 $ 5,833 Licenses 777 777 Software 117 117 Total intangibles 6,705 6,727 Accumulated amortization (2,215 ) (2,152 ) Intangible assets $ 4,490 $ 4,575
Schedule of Carrying Value of Intangible Assets	At January 31, 2020, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands): Fiscal Year ended October 31, 2020 (Remaining) $ 249 2021 332 2022 332 2023 332 2024 332 Thereafter 2,913 Total $ 4,490

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Jan. 31, 2020
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	The following table represents the major components of accrued expenses (in thousands): January 31, 2020 October 31, 2019 Salaries and other compensation $ 1,108 $ 158 Vendors 1,189 3,194 Professional fees 360 126 Total accrued expenses $ 2,657 $ 3,478

Common Stock Purchase Warrant_2

Common Stock Purchase Warrants and Warrant Liability (Tables)	3 Months Ended
	Jan. 31, 2020
Common Stock Purchase Warrants And Warrant Liability
Schedule of Outstanding Warrants	As of January 31, 2020, there were outstanding warrants to purchase 5,405,726 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows: Exercise Number of Shares Expiration Date Summary of Warrants $ - 334,838 July 2024 July 2019 Public Offering $ 281.25 25 N/A Other Warrants $ 0.372 70,863 September 2024 September 2018 Public Offering $ 1.25 5,000,000 July 2025 January 2020 Public Offering Grand Total 5,405,726 As of October 31, 2019, there were outstanding warrants to purchase 432,142 shares of our common stock with exercise prices ranging from $0 to $281.25 per share. Information on the outstanding warrants is as follows: Exercise Number of Shares Expiration Date Summary of Warrants $ - 359,838 July 2024 July 2019 Public Offering $ 281.25 25 N/A Other Warrants $ 0.372 72,279 September 2024 September 2018 Public Offering Grand Total 432,142
Schedule of Warrants Activity	A summary of warrant activity was as follows (In thousands, except share and per share data): Shares Weighted Weighted Aggregate Outstanding and exercisable warrants at October 31, 2019 432,142 $ 0.08 4.76 $ 114,069 Issued 5,000,000 $ 1.25 Exercised* (26,416 ) $ 0.24 Outstanding and exercisable warrants at January 31, 2020 5,405,726 $ 1.16 5.40 $ 322,542 * Includes the cashless exercise of 25,000 warrants that resulted in the issuance of 25,000 shares of common stock.
Schedule of Assumptions Used in Warrant Liability	In measuring the warrant liability at January 31, 2020 and October 31, 2019, the Company used the following inputs in its Monte Carlo simulation model: January 31, 2020 October 31, 2019 Exercise Price $ 0.37 $ 0.37 Stock Price $ 0.86 $ 0.32 Expected Term 4.62 years 4.87 years Volatility % 103.18 % 100.99 % Risk Free Rate 1.32 % 1.51 %

Share Based Compensation (Table

Share Based Compensation (Tables)	3 Months Ended
	Jan. 31, 2020
Share-based Payment Arrangement [Abstract]
Summary of Share Based Compensation Expense	The following table summarizes share-based compensation expense included in the condensed statements of operations (in thousands): Three Months Ended January 31, 2020 2019 Research and development $ 91 $ 323 General and administrative 151 299 Total $ 242 $ 622
Summary of RSU Activity and Related Information	A summary of the Company’s RSU activity and related information for the three months ended January 31, 2020 is as follows: Number of Weighted-Average Grant Unvested as of October 31, 2019 14,706 $ 47.62 Vested (2,957 ) 124.77 Cancelled (105 ) 101.72 Unvested as of January 31, 2020 11,644 $ 27.53
Summary of Changes in Stock Option Plan	A summary of changes in the stock option plan for the three months ended January 31, 2020 is as follows: Number of Weighted-Average Outstanding at October 31, 2019 560,490 $ 71.56 Canceled or Expired (7,044 ) 24.10 Outstanding at January 31, 2020 553,446 72.17 Vested and Exercisable at January 31, 2020 268,371 $ 141.37
Summary of Fair Value of Stock Options Granted of BSM	In determining the fair value of the stock options granted during the three months ended January 31, 2019, the Company used the following inputs in its Black-Scholes Merton (“BSM”) model (no options were granted during the three months ended January 31, 2020): Three Months Ended Expected Term 5.50-6.51 years Expected Volatility 90.29%-99.32 % Expected Dividends 0 % Risk Free Interest Rate 2.65%-3.15 %

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	3 Months Ended
	Jan. 31, 2020
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earnings Per Share	Basic and diluted earnings per share is calculated as follows (in thousands, except share and per share data): Three Months Ended January 31, 2020 2019 Numerator : Net (loss) income $ (7,857 ) $ 12,817 Earnings attributable to common stockholders – basic and diluted (7,857 ) 12,817 Denominator: Weighted-average number of common shares used in earnings per share - basic 51,412,408 4,642,718 Effect of dilutive stock options - 99 Weighted-average number of common shares used in earnings per share - diluted 51,412,408 4,642,817 Earnings per share – basic and diluted $ (0.15 ) $ 2.76
Schedule of Diluted Weighted-Average Shares Outstanding	The following potentially dilutive securities, prior to the use of the treasury stock method, have been excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive: As of January 31, 2020 2019 Warrants 5,405,726 944,636 Stock Options 553,446 383,292 Restricted Stock Units 11,644 20,258 Total 5,970,816 1,348,186

Leases (Tables)

Leases (Tables)	3 Months Ended
	Jan. 31, 2020
Leases [Abstract]
Schedule of Supplemental Balance Sheet Related to Leases	Supplemental balance sheet information related to leases as of January 31, 2020 was as follows (in thousands): Operating Leases:  Operating lease right-of-use assets $ 5,402 Operating lease liability $ 857 Operating lease liability, net of current portion 5,788 Total operating lease liabilities $ 6,645
Schedule of Lease Expenses	Supplemental lease expense related to leases was as follows (in thousands): Lease Cost (in thousands) Statements of Operations Classification For the Three Operating lease cost General and administrative 290 Short-term lease cost General and administrative 85 Variable lease cost General and administrative $ 141 Total lease expense $ 516
Schedule of Other Information Related to Leases	Other information related to leases where the Company is the lessee is as follows: For the Three Weighted-average remaining lease term 5.8 years Weighted-average discount rate 6.5 %
Schedule of Cash Flow Information Related to Leases	Supplemental cash flow information related to operating leases was as follows: For the Three Cash paid for operating lease liabilities $ 300
Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases	Future minimum lease payments under non-cancellable leases as of January 31, 2020 were as follows: Fiscal Year ended October 31, 2020 (Remaining) $ 933 2021 1,318 2022 1,369 2023 1,395 2024 1,419 Thereafter 1,564 Total minimum lease payments 7,998 Less: Imputed interest (1,353 ) Total $ 6,645
Schedule of Future Minimum Payments Under Operating Lease	Under ASC 840, future minimum payments under the Company’s operating lease were as follows (in thousands): Fiscal Year ended October 31, 2020 $ 1,233 2021 1,318 2022 1,369 2023 1,395 2024 1,419 Thereafter 1,564 Total $ 8,298

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Jan. 31, 2020
Equity [Abstract]
Summary of Stockholders Equity	A summary of the changes in stockholders’ equity for the three months ended January 31, 2020 and 2019 is presented below (in thousands, except share data): Preferred Stock Common Stock Additional Accumulated Total Shares Amount Shares Amount Capital Deficit Equity Balance at November 1, 2018 - $ - 4,634,189 $ 5 $ 391,703 $ (367,657 ) $ 24,051 Stock based compensation - - 9,811 - 622 - 622 Tax withholdings paid on equity awards - - - - (11 ) - (11 ) Tax shares sold to pay for tax withholdings on equity awards - - - - 11 - 11 Issuance of shares to employees under ESPP Plan - - 2,007 - 9 - 9 ESPP Expense - - - - 1 1 Net Income - - - - - 12,817 12,817 Balance at January 31, 2019 - $ - 4,646,007 $ 5 $ 392,335 $ (354,840 ) $ 37,500 Preferred Stock Common Stock Additional Accumulated Total Shares Amount Shares Amount Capital Deficit Equity Balance at November 1, 2019 - $ - 50,201,671 $ 50 $ 423,750 $ (384,269 ) $ 39,531 Stock based compensation - - 2,957 - 242 - 242 Advaxis public offerings - - 10,000,000 10 9,618 - 9,628 Warrant exercises - - 26,416 - 2 - 2 Issuance of shares to employees under ESPP Plan - - 5,555 - 2 - 2 Net Income - - - - - (7,857 ) (7,857 ) Balance at January 31, 2020 - $ - 60,236,599 $ 60 $ 433,614 $ (392,126 ) $ 41,548

Fair Value (Tables)

Fair Value (Tables)	3 Months Ended
	Jan. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of January 31, 2020 and October 31, 2019: January 31, 2020 Level 1 Level 2 Level 3 Total Common stock warrant liability, warrants exercisable at $0.372 through September 2024 - - $ 54 $ 54 October 31, 2019 Level 1 Level 2 Level 3 Total Common stock warrant liability, warrants exercisable at $0.372 through September 2024 - - $ 19 $ 19
Schedule of Changes in Fair Value of Warrant Liabilities	The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities: January 31, 2020 Beginning balance $ 19 Warrant Exercises (2 ) Change in fair value 37 Ending Balance $ 54

Nature of Operations (Details N

Nature of Operations (Details Narrative) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended		76 Months Ended
	Jan. 31, 2020	Jan. 31, 2020	Jan. 31, 2019	Oct. 31, 2019	Oct. 31, 2018	Jan. 31, 2020
Proceeds from public offering	$ 9,600	$ 10,500				$ 302,700
Cash and cash equivalents	34,156	34,156		$ 32,363		34,156
Operating expenses		7,889	$ 9,373	$ 38,900	$ 76,400
Cash balance funds raised	$ 10,500	10,500				$ 10,500
Proceeds from cash balance funds		9,600
Fiscal Year 2020 [Member]
Operating expenses		29,000
Non-recurring costs		$ 6,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Basis of Presentation (Details Narrative) - USD ($) $ in Thousands	Jan. 31, 2020	Nov. 02, 2019	Oct. 31, 2019
Operating lease liability	$ 857
Right to use asset	$ 5,402
ASC 842 [Member]
Operating lease liability		$ 6,800
Right to use asset		5,600
Accrued rent liability, current		900
Lease incentive obligation, current		$ 300

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 229	$ 285

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jan. 31, 2020	Oct. 31, 2019
Property, Plant and Equipment [Abstract]
Leasehold improvements	$ 2,335	$ 2,335
Laboratory equipment	3,405	3,405
Furniture and fixtures	744	744
Computer equipment	409	409
Construction in progress	83	83
Total property and equipment	6,976	6,976
Accumulated depreciation and amortization	(2,855)	(2,626)
Net property and equipment	$ 4,121	$ 4,350

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Finite lived patents expirations year	The expirations of the existing patents range from 2020 to 2040
Book value patent applications, net	$ 232	$ 244
Intangible asset amortization expense	91	96
General and Administrative [Member]
Intangible asset amortization expense	$ 100	$ 100

Intangible Assets - Summary of

Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	Jan. 31, 2020	Oct. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 5,811	$ 5,833
License	777	777
Software	117	117
Total intangibles	6,705	6,727
Accumulated amortization	(2,215)	(2,152)
Net Intangible assets	$ 4,490	$ 4,575

Intangible Assets - Schedule of

Intangible Assets - Schedule of Carrying Value of Intangible Assets (Details) $ in Thousands	Jan. 31, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2020 (Remaining)	$ 249
2021	332
2022	332
2023	332
2024	332
Thereafter	2,913
Total	$ 4,490

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Jan. 31, 2020	Oct. 31, 2019
Payables and Accruals [Abstract]
Salaries and other compensation	$ 1,108	$ 158
Vendors	1,189	3,194
Professional fees	360	126
Total accrued expenses	$ 2,657	$ 3,478

Common Stock Purchase Warrant_3

Common Stock Purchase Warrants and Warrant Liability (Details Narrative) - $ / shares	Jan. 31, 2020	Oct. 31, 2019
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock	5,405,726	432,142
Exercise price	$ 0.372	$ 0.372
Equity Warrants [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock	5,334,863	359,863
Warrants outstanding	5,405,726	432,142
Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Number of warrants to purchase common stock	70,863	72,279
Warrants outstanding	5,405,726	432,142
Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise price	$ 0	$ 0
Minimum [Member] | Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Exercise price	0.372
Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise price	281.25	$ 281.25
Maximum [Member] | Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Exercise price	$ 22.50

Common Stock Purchase Warrant_4

Common Stock Purchase Warrants and Warrant Liability - Schedule of Outstanding Warrants (Details) - $ / shares	3 Months Ended	12 Months Ended
	Jan. 31, 2020	Oct. 31, 2019
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.372	$ 0.372
Number of Shares Underlying Warrants	5,405,726	432,142
Exercise Price Range One [Member]
Class of Warrant or Right [Line Items]
Exercise Price
Number of Shares Underlying Warrants	334,838	359,838
Expiration Date	Jul. 31, 2024	Jul. 31, 2024
Summary of Warrants	July 2019 Public Offering	July 2019 Public Offering
Exercise Price Range Two [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 281.25	$ 281.25
Number of Shares Underlying Warrants	25	25
Summary of Warrants	Other Warrants	Other Warrants
Exercise Price Range Three [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.372	$ 0.372
Number of Shares Underlying Warrants	70,863	72,279
Expiration Date	Sep. 30, 2024	Sep. 30, 2024
Summary of Warrants	September 2018 Public Offering	September 2018 Public Offering
Exercise Price Range Four [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 1.25
Number of Shares Underlying Warrants	5,000,000
Expiration Date	Jul. 31, 2025
Summary of Warrants	January 2020 Public Offering

Common Stock Purchase Warrant_5

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Jan. 31, 2020USD ($)$ / sharesshares
Common Stock Purchase Warrants And Warrant Liability
Number of Warrants, Outstanding and exercisable warrants, Beginning balance | shares	432,142
Number of Warrants, Issued | shares	5,000,000
Number of Warrants, Exercised | shares	(26,416)	[1]
Number of Warrants, Outstanding and exercisable warrants, Ending balance | shares	5,405,726
Weighted Average Exercise Price, Outstanding and exercisable warrants, Beginning | $ / shares	$ 0.08
Weighted Average Exercise Price, Issued | $ / shares	1.25
Weighted Average Exercise Price, Exercised | $ / shares	0.24	[1]
Weighted Average Exercise Price, Outstanding and exercisable warrants, Ending | $ / shares	$ 1.16
Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Beginning	4 years 9 months 3 days
Weighted Average Remaining Contractual Life In Years, Outstanding and exercisable warrants, Ending balance	5 years 4 months 24 days
Aggregate Intrinsic Value, Beginning | $	$ 114,069
Aggregate Intrinsic Value, Ending | $	$ 322,542
[1]	Includes the cashless exercise of 25,000 warrants that resulted in the issuance of 25,000 shares of common stock.

Common Stock Purchase Warrant_6

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) (Parenthetical)	3 Months Ended
	Jan. 31, 2020shares
Common Stock Purchase Warrants And Warrant Liability
Cashless warrant exercise	25,000
Number of common stock shares issued	25,000

Common Stock Purchase Warrant_7

Common Stock Purchase Warrants and Warrant Liability - Schedule of Assumptions Used in Warrant Liability (Details) - Warrant Liability [Member]	Jan. 31, 2020	Oct. 31, 2019$ / shares
Exercise Price [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	0.37	0.37
Stock Price [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	0.86	0.32
Expected Term [Member]
Class of Warrant or Right [Line Items]
Warrants, term	4 years 7 months 13 days	4 years 10 months 14 days
Volatility [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input percentage	103.18%	100.99%
Risk Free Interest Rate [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input percentage	1.32%	1.51%

Share Based Compensation (Detai

Share Based Compensation (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Unrecognized compensation cost related to non-vested stock option awards	$ 1,100
Unrecognized compensation cost related to non-vested remaining weighted average vesting period	1 year 4 months 28 days
Aggregate intrinsic value of non-vested RSU	$ 0
Stock compensation expense	242	$ 622
Compensation cost related to outstanding stock options	$ 200	$ 300
2018 Employee Stock Purchase Plan [Member]
Number of shares issued under employee stock purchase plan	5,555
Restricted Stock Units (RSUs) [Member]
Unrecognized compensation cost related to non-vested stock option awards	$ 200
Unrecognized compensation cost related to non-vested remaining weighted average vesting period	1 year 18 days
Aggregate intrinsic value of non-vested RSU	$ 10
Employee Stock Awards [Member]
Share-based compensation, common stock, shares	2,957	9,847
Stock compensation expense	$ 56	$ 300

Share Based Compensation - Summ

Share Based Compensation - Summary of Share Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Share-based compensation expense	$ 242	$ 622
Research and Development [Member]
Share-based compensation expense	91	323
General and Administrative [Member]
Share-based compensation expense	$ 151	$ 299

Share Based Compensation - Su_2

Share Based Compensation - Summary of RSU Activity and Related Information (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Oct. 31, 2020$ / sharesshares
Number of RSUs, Unvested Beginning Balance | shares	14,706
Number of RSUs, Vested | shares	(2,957)
Number of RSUs, Cancelled | shares	(105)
Number of RSUs, Unvested Ending Balance | shares	11,644
Weighted-Average Grant Date Fair Value, Unvested Beginning Balance | $ / shares	$ 47.62
Weighted-Average Grant Date Fair Value, Vested | $ / shares	124.77
Weighted-Average Grant Date Fair Value, Cancelled | $ / shares	101.72
Weighted-Average Grant Date Fair Value, Unvested Ending Balance | $ / shares	$ 27.53

Share Based Compensation - Su_3

Share Based Compensation - Summary of Changes in Stock Option Plan (Details)	3 Months Ended
	Jan. 31, 2020$ / sharesshares
Share-based Payment Arrangement [Abstract]
Number of Options, Beginning Balance | shares	560,490
Number of Options, Cancelled or Expired | shares	(7,044)
Number of Options, Ending Balance | shares	553,446
Number of Options, Vested and Exercisable | shares	268,371
Weighted-Average Exercise Price, Outstanding, Beginning | $ / shares	$ 71.56
Weighted-Average Exercise Price, Cancelled or Expired | $ / shares	24.10
Weighted-Average Exercise Price, Outstanding, Ending | $ / shares	72.17
Weighted-Average Exercise Price, Vested and Exercisable | $ / shares	$ 141.37

Share Based Compensation - Su_4

Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details)	3 Months Ended
	Jan. 31, 2020
Expected Dividends	0.00%
Minimum [Member]
Expected Term	5 years 6 months
Expected Volatility	90.29%
Risk Free Interest Rate	2.65%
Maximum [Member]
Expected Term	6 years 6 months 3 days
Expected Volatility	99.32%
Risk Free Interest Rate	3.15%

Net Income (Loss) Per Share - S

Net Income (Loss) Per Share - Schedule of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Earnings Per Share [Abstract]
Net (loss) income	$ (7,857)	$ 12,817
Earnings attributable to common stockholders - basic and diluted	$ (7,857)	$ 12,817
Weighted-average number of common shares used in earnings per share - basic	51,747,246	4,642,718
Effect of dilutive stock options		$ 99
Weighted-average number of common shares used in earnings per share - diluted	51,747,246	4,642,817
Earnings per share - basic and diluted	$ (0.15)	$ 2.76

Net Income (Loss) Per Share -_2

Net Income (Loss) Per Share - Schedule of Diluted Weighted-Average Shares Outstanding (Details) - shares	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Total	5,970,816	1,348,186
Stock Options [Member]
Total	5,405,726	944,636
Restricted Stock Units [Member]
Total	553,446	383,292
Pre-funded Warrants [Member]
Total	11,644	20,258

Collaboration and Licensing A_2

Collaboration and Licensing Agreements (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Revenue	$ 3	$ 19,689
Aratana Agreement [Member] | Royalty [Member]
Revenue	$ 3	$ 2

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - Especificos Stendhal SA de CV [Member] $ in Thousands	Sep. 19, 2018USD ($)
Damages sought value by plaintiff	$ 3,000
Litigation expense	300
Due from related party	$ 3,000

Leases (Details Narrative)

Leases (Details Narrative) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jan. 31, 2020	Oct. 31, 2019	Oct. 31, 2018
Leases [Abstract]
Operating lease expiration	Nov. 30, 2025
Security deposit	$ 182
Rent expense		$ 1,200	$ 1,200

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Balance Sheet Related to Leases (Details) - USD ($) $ in Thousands	Jan. 31, 2020	Oct. 31, 2019
Leases [Abstract]
Operating lease right-of-use assets	$ 5,402
Operating lease liability	857
Operating lease liability, net of current portion	5,788
Total operating lease liabilities	$ 6,645

Leases - Schedule of Lease Expe

Leases - Schedule of Lease Expenses (Details) - General and Administrative [Member] $ in Thousands	3 Months Ended
	Jan. 31, 2020USD ($)
Operating lease cost	$ 290
Short-term lease cost	85
Variable lease cost	141
Total lease expense	$ 516

Leases - Schedule of Other Info

Leases - Schedule of Other Information Related to Leases (Details)	Jan. 31, 2020
Leases [Abstract]
Weighted-average remaining lease term	5 years 9 months 18 days
Weighted-average discount rate	6.50%

Leases - Schedule of Cash Flow

Leases - Schedule of Cash Flow Information Related to Leases (Details) $ in Thousands	3 Months Ended
	Jan. 31, 2020USD ($)
Leases [Abstract]
Cash paid for operating lease liabilities	$ 300

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details) $ in Thousands	Jan. 31, 2020USD ($)
Leases [Abstract]
2020 (Remaining)	$ 933
2021	1,318
2022	1,369
2023	1,395
2024	1,419
Thereafter	1,564
Total minimum lease payments	7,998
Less: Imputed interest	(1,353)
Total	$ 6,645

Leases - Schedule of Future M_2

Leases - Schedule of Future Minimum Payments Under Operating Lease (Details) $ in Thousands	Jan. 31, 2020USD ($)
Leases [Abstract]
2020	$ 1,233
2021	1,318
2022	1,369
2023	1,395
2024	1,419
Thereafter	1,564
Total	$ 8,298

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended	76 Months Ended
	Jan. 31, 2020	Jan. 31, 2020	Jan. 31, 2020	Oct. 31, 2019
Number of shares issued, shares		25,000
Number of warrants to purchase common stock	5,405,726	5,405,726	5,405,726	432,142
Exercise Price	$ 0.372	$ 0.372	$ 0.372	$ 0.372
Net proceeds from offering	$ 9,600	$ 10,500	$ 302,700
Underwritten Public Offering [Member]
Number of shares issued, shares	10,000
Public Offering [Member]
Share price per share	$ 1.05	$ 1.05	$ 1.05
Proceeds from sale of common shares	$ 10,500
Private Placement [Member]
Number of warrants to purchase common stock	5,000,000	5,000,000	5,000,000
Exercise Price	$ 1.25	$ 1.25	$ 1.25

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stockholders Equity (Details) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Beginning balance	$ 39,531	$ 24,051
Stock based compensation	242	622
Tax withholdings paid on equity awards		(11)
Tax shares sold to pay for tax withholdings on equity awards		11
Issuance of shares to employees under ESPP Plan	2	9
ESPP Expense		1
Advaxis public offerings	$ 9,628
Advaxis public offerings, shares	25,000
Warrant exercises	$ 2
Net Income	(7,857)	12,817
Ending balance	41,548	37,500
Preferred Stock [Member]
Beginning balance
Beginning balance, shares
Stock based compensation
Stock based compensation, shares
Tax withholdings paid on equity awards
Tax shares sold to pay for tax withholdings on equity awards
Issuance of shares to employees under ESPP Plan
Issuance of shares to employees under ESPP Plan, shares
ESPP Expense
Advaxis public offerings
Advaxis public offerings, shares
Warrant exercises
Warrant exercises, shares
Net Income
Ending balance
Ending balance, shares
Common Stock [Member]
Beginning balance	$ 50	$ 5
Beginning balance, shares	50,201,671	4,634,189
Stock based compensation
Stock based compensation, shares	2,957	9,811
Tax withholdings paid on equity awards
Tax shares sold to pay for tax withholdings on equity awards
Issuance of shares to employees under ESPP Plan
Issuance of shares to employees under ESPP Plan, shares	5,555	2,007
ESPP Expense
Advaxis public offerings	$ 10
Advaxis public offerings, shares	10,000,000
Warrant exercises
Warrant exercises, shares	26,416
Net Income
Ending balance	$ 60	$ 5
Ending balance, shares	60,236,599	4,646,007
Additional Paid-In Capital [Member]
Beginning balance	$ 423,750	$ 391,703
Stock based compensation	242	622
Tax withholdings paid on equity awards		(11)
Tax shares sold to pay for tax withholdings on equity awards		11
Issuance of shares to employees under ESPP Plan	2	9
ESPP Expense		1
Advaxis public offerings	9,618
Warrant exercises	2
Net Income
Ending balance	433,614	392,335
Accumulated Deficit [Member]
Beginning balance	(384,269)	(367,657)
Stock based compensation
Tax withholdings paid on equity awards
Tax shares sold to pay for tax withholdings on equity awards
Issuance of shares to employees under ESPP Plan
ESPP Expense
Advaxis public offerings
Net Income	(7,857)	12,817
Ending balance	$ (392,126)	$ (354,840)

Fair Value - Schedule of Fair V

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Jan. 31, 2020	Oct. 31, 2019
Common stock warrant liability, warrants exercisable	$ 54	$ 19
Fair Value, Inputs, Level 1 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 2 [Member]
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 3 [Member]
Common stock warrant liability, warrants exercisable	$ 54	$ 19

Fair Value - Schedule of Fair_2

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) (Parenthetical) - $ / shares	Jan. 31, 2020	Oct. 31, 2019
Fair Value Disclosures [Abstract]
Warrant exercise price per share	$ 0.372	$ 0.372

Fair Value - Schedule of Change

Fair Value - Schedule of Changes in Fair Value of Warrant Liabilities (Details) $ in Thousands	3 Months Ended
	Jan. 31, 2020USD ($)
Beginning balance	$ 19
Warrant exercises	2
Ending Balance	54
Warrant Liability [Member]
Beginning balance	19
Warrant exercises	(2)
Change in fair value	37
Ending Balance	$ 54